Indications that paraoxonase-1 contributes to plasma high density lipoprotein levels in familial hypercholesterolemia

Journal of Lipid Research

Volumn 46, Issue 3, 2005, Pages 445-451

  Van Himbergen, Thomas M ^a,b   Roest, Mark ^a   De Graaf, Jacqueline ^b   Jansen, Eugène H J M ^c   Hattori, Hiroaki ^d   Kastelein, John J P ^e   Voorbij, Hieronymus A M ^a   Stalenhoef, Anton F H ^b   Van Tits, Lambertus J H ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^d BML   (Japan)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Antioxidants; Atherosclerosis; Polymorphisms

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; OXIDIZED LOW DENSITY LIPOPROTEIN; PARAOXON; PHENYLACETIC ACID; ARYLDIALKYLPHOSPHATASE; PLACEBO; PON1 PROTEIN, HUMAN;

ARTICLE; ATHEROSCLEROSIS; CAROTID ARTERY; CORRELATION ANALYSIS; DRUG EFFECT; ENZYME ACTIVITY; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; GENETIC VARIABILITY; GENOTYPE; HUMAN; HYDROLYSIS; IMMUNOASSAY; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; HYPERLIPOPROTEINEMIA TYPE 2; METABOLISM; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

ARYLDIALKYLPHOSPHATASE; CHOLESTEROL, HDL; DOUBLE-BLIND METHOD; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENOTYPE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; MALE; PLACEBOS; PROSPECTIVE STUDIES; VARIATION (GENETICS);

EID: 20744452641     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M400052-JLR200     Document Type: Article

References (47)

1. Mackness, M. I., S. Arrol, and P. N. Durrington. 1991. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett. 286: 152-154.
2. Mertens, A., and P. Holvoet. 2001. Oxidized LDL and HDL: antagonists in atherothrombosis. FASEB J. 15: 2073-2084.
3. Shih, D. M., L. Gu, Y. R. Xia, M. Navab, W. F. Li, S. Hama, L. W. Castellani, C. E. Furlong, L. G. Costa, A. M. Fogelman, and A. J. Lusis. 1998. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature. 394: 284-287.
4. Aviram, M., M. Rosenblat, C. L. Bisgaier, R. S. Newton, S. L. Primo-Parmo, and B. N. La Du. 1998. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J. Clin. Invest. 101: 1581-1590.
5. Miller, G. J., and N. E. Miller. 1975. Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet. 1: 16-19.
6. Simpson, N. E. 1971. Serum arylesterase levels of activity in twins and their parents. Am. J. Hum. Genet. 23: 375-382.
7. Garin, M. C., R. W. James, P. Dussoix, H. Blanche, P. Passa, P. Froguel, and J. Ruiz. 1997. Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J. Clin. Invest. 99: 62-66.
8. Humbert, R., D. A. Adler, C. M. Disteche, C. Hassett, C. J. Omiecinski, and C. E. Furlong. 1993. The molecular basis of the human serum paraoxonase activity polymorphism. Nat. Genet. 3: 73-76.
9. Leus, F. R., M. E. Wittekoek, J. Prins, J. J. Kastelein, and H. A. Voorbij. 2000. Paraoxonase gene polymorphisms are associated with carotid arterial wall thickness in subjects with familial hypercholesterolemia. Atherosclerosis. 149: 371-377.
10. Wheeler, J. G., B. D. Keavney, H. Watkins, R. Collins, and J. Danesh. 2004. Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies. Lancet. 363: 689-695.
11. James, R. W., I. Leviev, and A. Righetti. 2000. Smoking is associated with reduced serum paraoxonase activity and concentration in patients with coronary artery disease. Circulation. 101: 2252-2257.
12. Nishio, E., and Y. Watanabe. 1997. Cigarette smoke extract inhibits plasma paraoxonase activity by modification of the enzyme's free thiols. Biochem. Biophys. Res. Commun. 236: 289-293.
13. Jarvik, G. P., N. T. Tsai, L. A. McKinstry, R. Wani, V. H. Brophy, R. J. Richter, G. D. Schellenberg, P. J. Heagerty, T. S. Hatsukami, and C. E. Furlong. 2002. Vitamin C and E intake is associated with increased paraoxonase activity. Arterioscler. Thromb. Vasc. Biol. 22: 1329-1333.
14. van der Gaag, M. S., A. van Tol, L. M. Scheek, R. W. James, R. Urgert, G. Schaafsma, and H. F. Hendriks. 1999. Daily moderate alcohol consumption increases serum paraoxonase activity: a dietcontrolled, randomised intervention study in middle-aged men. Atherosclerosis. 147: 405-410.
15. Smilde, T. J., S. Van Wissen, H. Wollersheim, M. D. Trip, J. J. Kastelein, and A. F. Stalenhoef. 2001. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet. 357: 577-581.
16. Mackness, B., R. Hunt, P. N. Durrington, and M. I. Mackness. 1997. Increased immunolocalization of paraoxonase, clusterin, and apolipoprotein A-I in the human artery wall with the progression of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 17: 1233-1238.
17. Blatter Garin, M. C., C. Abbott, S. Messmer, M. Mackness, P. Durrington, D. Pometta, and R. W. James. 1994. Quantification of human serum paraoxonase by enzyme-linked immunoassay: population differences in protein concentrations. Biochem. J. 304: 549-554.
18. Smilde, T. J., M. D. Trip, H. Wollersheim, S. Van Wissen, J. J. P. Kastelein, and A. F. H. Stalenhoef. 2000. Rationale, design and baseline characteristics of a clinical trial comparing the effects of robust vs conventional cholesterol lowering and intima media thickness in patients with familial hypercholesterolaemia: the Atorvastatin versus Simvastatin on Atherosclerosis Progression (ASAP) Study. Clin. Drug Invest. 20: 67-79.
19. Smilde, T. J., H. Wollersheim, H. van Langen, and A. F. Stalenhoef. 1997. Reproducibility of ultrasonographic measurements of different carotid and femoral artery segments in healthy subjects and in patients with increased intima-media thickness. Clin. Sci. (Lond.). 93: 317-324.
20. Leviev, I., and R. W. James. 2000. Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler. Thromb. Vasc. Biol. 20: 516-521.
21. Kujiraoka, T., T. Oka, M. Ishihara, T. Egashira, T. Fujioka, E. Saito, S. Saito, N. E. Miller, and H. Hattori. 2000. A sandwich enzyme-linked immunosorbent assay for human serum paraoxonase concentration. J. Lipid Res. 41: 1358-1363.
22. Richter, R. J., and C. E. Furlong. 1999. Determination of paraoxonase (PON1) status requires more than genotyping. Pharmacogenetics. 9: 745-753.
23. Eckerson, H. W., C. M. Wyte, and B. N. La Du. 1983. The human serum paraoxonase/arylesterase polymorphism. Am. J. Hum. Genet. 35: 1126-1138.
24. Saha, N., A. C. Roy, S. H. Teo, J. S. Tay, and S. S. Ratnam. 1991. Influence of serum paraoxonase polymorphism on serum lipids and apolipoproteins. Clin. Genet. 40: 277-282.
25. Blatter, M. C., R. W. James, S. Messmer, F. Barja, and D. Pometta. 1993. Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase. Eur. J. Biochem. 211: 871-879.
26. Oda, M. N., J. K. Bielicki, T. T. Ho, T. Berger, E. M. Rubin, and T. M. Forte. 2002. Paraoxonase 1 overexpression in mice and its effect on high-density lipoproteins. Biochem. Biophys. Res. Commun. 290: 921-927.
27. Brousseau, M. E., S. Santamarina-Fojo, B. L. Vaisman, D. Applebaum-Bowden, A. M. Berard, G. D. Talley, H. B. Brewer, Jr., and J. M. Hoeg. 1997. Overexpression of human lecithin:cholesterol acyltransferase in cholesterol-fed rabbits: LDL metabolism and HDL metabolism are affected in a gene dose-dependent manner. J. Lipid Res. 38: 2537-2547.
28. Wang, M., and M. R. Briggs. 2004. HDL: the metabolism, function, and therapeutic importance. Chem. Rev. 104: 119-137.
29. Gordon, D. J., J. L. Probstfield, R. J. Garrison, J. D. Neaton, W. P. Castelli, J. D. Knoke, D. R. Jacobs, Jr., S. Bangdiwala, and H. A. Tyroler. 1989. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 79: 8-15.
30. Campo, S., M. A. Sardo, G. Trimarchi, M. Bonaiuto, M. Castaldo, L. Fontana, A. Bonaiuto, A. Bitto, C. Saitta, and A. Saitta. 2004. The paraoxonase promoter polymorphism (-107)T>C is not associated with carotid intima-media thickness in Sicilian hypercholesterolemic patients. Clin. Biochem. 37: 388-394.
31. Schmidt, H., R. Schmidt, K. Niederkorn, A. Gradert, M. Schumacher, N. Watzinger, H. P. Hartung, and G. M. Kostner. 1998. Paraoxonase PON1 polymorphism Leu-Met54 is associated with carotid atherosclerosis: results of the Austrian Stroke Prevention Study. Stroke. 29: 2043-2048.
32. Koyama, H., T. Maeno, S. Fukumoto, T. Shoji, T. Yamane, H. Yokoyama, M. Emoto, T. Shoji, H. Tahara, M. Inaba, M. Hino, A. Shioi, T. Miki, and Y. Nishizawa. 2003. Platelet P-selectin expression is associated with atherosclerotic wall thickness in carotid artery in humans. Circulation. 108: 524-529.
33. Wohlin, M., J. Sundstrom, J. Arnlov, B. Andren, B. Zethelius, and L. Lind. 2003. Impaired insulin sensitivity is an independent predictor of common carotid intima-media thickness in a population sample of elderly men. Atherosclerosis. 170: 181-185.
34. Fortunato, G., P. Rubba, S. Panico, D. Trono, N. Tinto, C. Mazzaccara, M. De Michele, A. Iannuzzi, D. F. Vitale, F. Salvatore, and L. Sacchetti. 2003. A paraoxonase gene polymorphism, PON 1 (55), as an independent risk factor for increased carotid intima-media thickness in middle-aged women. Atherosclerosis. 167: 141-148.
35. Malin, R., A. Loimaala, A. Nenonen, M. Mercuri, I. Vuori, M. Pasanen, P. Oja, G. Bond, T. Koivula, and T. Lehtimaki. 2001. Relationship between high-density lipoprotein paraoxonase gene M/L55 polymorphism and carotid atherosclerosis differs in smoking and nonsmoking men. Metabolism. 50: 1095-1101.
36. Cao, H., A. Girard-Globa, A. Serusclat, S. Bernard, P. Bondon, S. Picard, F. Berthezene, and P. Moulin. 1998. Lack of association between carotid intima-media thickness and paraoxonase gene polymorphism in non-insulin dependent diabetes mellitus. Atherosclerosis. 138: 361-366.
37. Markus, H., Z. Kapozsta, R. Ditrich, C. Wolfe, N. Ali, J. Powell, M. Mendell, and M. Cullinane. 2001. Increased common carotid intima-media thickness in UK African Caribbeans and its relation to chronic inflammation and vascular candidate gene polymorphisms. Stroke. 32: 2465-2471.
38. Valabhji, J., A. J. McColl, M. Schachter, S. Dhanjil, W. Richmond, and R. S. Elkeles. 2001. High-density lipoprotein composition and paraoxonase activity in type I diabetes. Clin. Sci. (Lond.). 101: 659-670.
39. Mackness, M. I., S. Arrol, and P. N. Durrington. 1991. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett. 286: 152-154.
40. Mackness, M. I., S. Arrol, C. Abbott, and P. N. Durrington. 1993. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis. 104: 129-135.
41. Watson, A. D., J. A. Berliner, S. Y. Hama, B. N. La Du, K. F. Faull, A. M. Fogelman, and M. Navab. 1995. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J. Clin. Invest. 96: 2882-2891.
42. Lusis, A. J. 2000. Atherosclerosis. Nature. 407: 233-241.
43. Ross, R. 1999. Atherosclerosis - an inflammatory disease. N. Engl. J. Med. 340: 115-126.
44. Holvoet, P., J. Vanhaecke, S. Janssens, F. Van de Werf, and D. Collen. 1998. Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation. 98: 1487-1494.
45. Ridker, P. M., N. Rifai, L. Rose, J. E. Buring, and N. R. Cook. 2002. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N. Engl. J. Med. 347: 1557-1565.
46. Brophy, V. H., R. L. Jampsa, J. B. Clendenning, L. A. McKinstry, G. P. Jarvik, and C. E. Furlong. 2001. Effects of 5 regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. Am. J. Hum. Genet. 68: 1428-1436.
47. Davies, H. G., R. J. Richter, M. Keifer, C. A. Broomfield, J. Sowalla, and C. E. Furlong. 1996. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat. Genet. 14: 334-336.